Psychiatry and Neurology, Neurology · Peoria, IL
NPI
1922328103
Since 2010
Specialty
Psychiatry and Neurology, Neurology
Code 2084N0400X
Group practices
1
Medicare group memberships
Hospitals
5
Hospital affiliations
1001 Main St Ste 611
Peoria, IL, 61606
Phone (309) 495-0200
Groups this clinician bills Medicare through
Medicare paid, 2024
$178K
7,561 services
Medicare patients, 2024
324
Average age 71
Drug cost, 2024
$6.8M
2,307 prescriptions
Company payments, 2025
$125K
From 33 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Reuben M Valenzuela was code 99214 (office e&m - established), 313 times for 169 patients. In total Reuben M Valenzuela billed 7,561 services in 33 codes, and Medicare paid $178K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2022-12-30.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99214 Office E&M - Established | Office | 313 | 169 | $88.43 | $28K |
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Office | 307 | 172 | $12.45 | $3,822 |
| 99213 Office E&M - Established | Office | 237 | 171 | $62.60 | $15K |
| 36415 Venipuncture Blood Collection | Office | 139 | 110 | $7.86 | $1,093 |
| 92082 Vision, Hearing, and Speech Services | Office | 104 | 85 | $32.16 | $3,345 |
| 99204 Office E&M - New | Office | 89 | 89 | $109.18 | $9,717 |
| 92133 Computerized Ophthalmic Imaging | Office | 45 | 40 | $21.23 | $955 |
By year: 2022 $56K for 736 services; 2023 $219K for 6,792 services; 2024 $178K for 7,561 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 36415 Venipuncture Blood Collection | 139 | 110 | $7.86 | $1,093 |
Medicare prescription drug claims, 2024
In 2024, the drug Reuben M Valenzuela prescribed most often to Medicare patients was Gabapentin, with 230 prescriptions and refills. In total Reuben M Valenzuela wrote 2,307 Medicare prescriptions that cost $6.8M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Gabapentin Generic | 230 | 535 | 77 | $5,495 |
| Tizanidine Hcl Generic | 129 | 318 | 48 | $1,213 |
| Kesimpta Pen Ofatumumab | 120 | 128 | 16 | $1.2M |
| Baclofen Generic | 109 | 243 | 31 | $4,098 |
| Levetiracetam Generic | 108 | 216 | 23 | $3,649 |
| Pyridostigmine Bromide Generic | 69 | 168 | 26 | $5,487 |
| Carbidopa-Levodopa Carbidopa/Levodopa | 66 | 186 | 27 | $1,622 |
| Methylphenidate Hcl Generic | 59 | 59 | 11 | $1,273 |
| Oxcarbazepine Generic | 58 | 136 | 21 | $1,408 |
| Dextroamphetamine-Amphetamine Dextroamphetamine/Amphetamine | 55 | 55 | 11 | $1,773 |
| Donepezil Hcl Generic | 51 | 109 | 14 | $554 |
| Prednisone Generic | 48 | 91 | 21 | $251 |
| Dalfampridine Er Dalfampridine | 47 | 59 | Under 11 | $31K |
| Propranolol Hcl Generic | 46 | 115 | 15 | $430 |
| Pregabalin Generic | 43 | 104 | 18 | $976 |
Brand drugs: - claims; generic drugs: 1,812 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Reuben M Valenzuela $125K ($125K in general payments such as food, travel and fees) from 33 companies. The largest payer was Biogen, Inc. with $23K.
| Company | Payments | Amount |
|---|---|---|
| Biogen, Inc. BIIB | 25 | $23K |
| EMD Serono, Inc. MRK.DE | 21 | $22K |
| Vanda Pharmaceuticals Inc. VNDA | 13 | $17K |
| Pfizer Inc. PFE | 18 | $14K |
| Janssen Biotech, Inc. JNJ | 18 | $14K |
| UCB, Inc. UCB.BR | 20 | $12K |
| Alexion Pharmaceuticals, Inc. AZN | 12 | $9,877 |
| TG Therapeutics, Inc. TGTX | 31 | $6,841 |
| E.R. Squibb & Sons, L.L.C. BMY | 2 | $3,603 |
| Genzyme Corporation SNY | 7 | $368 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.